Action ELGXQ ENDOLOGIX, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Endologix, Inc.

Actions

ELGXQ

US29266S3040

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Endologix LLC Announces Online Publication of the One-Year Results of the DETOUR2 Trial in the Journal of Vascular Surgery
Endologix LLC Appoints Mike Mathias as Chief Commercial Officer
Endologix LLC Announces That Art Taylor Joins Board of Directors
Endologix LLC Appoints Scott Ward Joins Board of Directors
Endologix LLC Announces Appointment of Scott Ward as Board of Directors
Endologix LLC Announces the U. S. Centers for Medicare & Medicaid Services Grants Transitional Pass-Through Payment for the Detour System
Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session
Endologix Llc Announces the U. S. Centers for Medicare & Medicaid Services Grants New Technology Add-On Payment for the Detour System
Endologix LLC Appoints Lucas Buchanan to its Board of Directors
Endologix Announces First Patients Treated with the DETOUR?? System, Advancing Treatment for Complex Peripheral Artery Disease
Endologix LLC Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting
Endologix Llc Receives Fda Approval of the Detour System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with Pad
Endologix LLC Announces 150Th Patient Enrolled in JAGUAR Randomized Controlled Trial
Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session
Endologix LLC Announced the Five-Year Results from the Leopard Randomized Controlled Trial
Endologix LLC Announces the Elevate
Endologix LLC Submits Premarket Approval Application to FDA for the DETOUR System
Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting
Endologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA
Endologix Appoints Dr. Matthew Thompson as CEO
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ELGXQ
  4. Actualités Endologix, Inc.
  5. Autres langues